消癌平联合XELOX方案对晚期胃癌恶性分子表达的影响

摘要

Objective To discuss the Xiaoaiping combined with capecitabine combined with oxaliplatin (XELOX regimen) in the treatment of advanced gastric carcinoma and its effect on the expression of malignant molecule for the therapeutic evaluation of this treatment program.Methods Fifty-six cases of advanced gastric cancer patients from May 2013 to Dece 2015 admitted to the Second People's Hospital of Pingdingshan were recruited as research subjects and were randomly assigned into observation group and control group with 28 cases in each;the observation group was treated with Xiaoaiping combined with XELOX chemotherapy, while the control group were treated with XELOX chemotherapy.After four cycles of chemotherapy, the serum was collected and the content of tumor markers was measured.The tumor lesions were collected and the expressions of apoptotic molecules and invasive molecules were determined.Results After four cycles of treatment, carcinoembryonic antigen in serum (CEA), tumor markers CA199、CA153、CA724、thymidine kinase 1 (TK-1) and the content of gastric carcinoma matrix metalloproteinase 2 (MMP), matrix metalloproteinases (MMP7 7), matrix metalloproteinase-9 (MMP9) and matrix metalloproteinase-14 (MMP14) were significantly lower than those of the control group, and the difference was statistically significant (P<0.05);the apoptosis protein in gastric cancer (Bax) and apoptosis related factor ligand (FasL), fatty acid synthase (Fas) and caspase-3 (caspase-3), cysteine aspartic acid specific protease 9 (caspase-9) were significantly higher than those in control group, and the difference was statistically significant (P<0.05).Conclusion The clinical curative effect of Xiaoaiping combined with XELOX regimen in the treatment of advanced gastric cancer is significant, which can more effectively reduce tumor markers related genes and inhibit the expression of invasion related genes.%目的 探讨消癌平联合奥沙利铂联合卡培他滨(XELOX方案)治疗晚期胃癌恶性分子表达的影响,评价该治疗方案的疗效.方法 选择2013年5月至2015年12月在平顶山市第二人民医院接受化疗的56例进展期胃癌患者作为研究对象,并随机分为观察组及对照组各28例,观察组患者给予消癌平联合XELOX方案化疗、对照组患者给予XELOX方案化疗.化疗4个周期后,测定肿瘤标志物的含量及凋亡分子和侵袭分子的表达量.结果 治疗4个周期后,观察组患者血清中癌胚抗原(CEA)、肿瘤标志物CA199、CA153、CA724、胸苷激酶1(TK-1)的含量以及胃癌组织中基质金属蛋白酶-2(MMP2)、基质金属蛋白酶-7(MMP7)、基质金属蛋白酶-9(MMP9)、基质金属蛋白酶-14(MMP14)的含量均低于对照组,差异有统计学意义(P<0.05);胃癌组织中凋亡蛋白(Bax)、凋亡相关因子配体(FasL)、脂肪酸合成酶(Fas)、半胱氨酸天冬氨酸特异性蛋白酶-3(caspase-3)、半胱氨酸天冬氨酸特异性蛋白酶-9(caspase-9)的含量高于对照组,差异有统计学意义(P<0.05).结论 消癌平联合XELOX方案治疗晚期胃癌的临床疗效显著,能够更为有效地降低肿瘤标志物的含量、促进凋亡相关基因表达、抑制侵袭相关基因表达.